Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1995 Mar 28;92(7):2691-5.
doi: 10.1073/pnas.92.7.2691.

Endothelin 1 mediates ex vivo coronary vasoconstriction caused by exogenous and endogenous cytokines

Affiliations

Endothelin 1 mediates ex vivo coronary vasoconstriction caused by exogenous and endogenous cytokines

P Klemm et al. Proc Natl Acad Sci U S A. .

Abstract

Treatment of rats with cytokines has been associated with an increase in the circulating levels of endothelin 1 (ET-1). Here we show that administration of tumor necrosis factor alpha (TNF-alpha; 4 micrograms.kg-1) to anesthetized rats caused within 15 min a strong elevation in the circulating levels of ET-1. This was associated with a striking coronary vasoconstriction in hearts from these animals when they were removed and perfused in vitro by the Langendorff technique. This vasoconstriction was largely overcome by treatment with either the endothelin type A (ETA) receptor antagonist FR 139317 or antibody against ET-1. Furthermore, it was mimicked by in vivo exposure to exogenous ET-1. Endogenously produced TNF-alpha may also cause such a coronary vasoconstriction, for treatment with interleukin 2 (600 micrograms.kg-1) produced an increase in coronary perfusion pressure that correlated with the increases in circulating TNF-alpha. This coronary vasoconstriction was substantially reversed by treatment either with antibody against TNF-alpha or with FR 139317. We suggest, therefore, that cytokine-driven changes in the production of ET-1 are key events in the development of vascular pathologies.

PubMed Disclaimer

References

    1. Peptides. 1991 Sep-Oct;12(5):1095-103 - PubMed
    1. Lancet. 1991 Dec 21-28;338(8782-8783):1542-5 - PubMed
    1. J Cardiovasc Pharmacol. 1991 Dec;18(6):895-903 - PubMed
    1. Proc Natl Acad Sci U S A. 1992 Sep 1;89(17):8371-5 - PubMed
    1. Drug Saf. 1992 Nov-Dec;7(6):417-33 - PubMed

Publication types

MeSH terms

LinkOut - more resources